News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx Reports First Quarter 2019 Financial Results and Recent Highlights
-- Succession of topline data readouts expected, starting with Pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA Vasculitis in Q4 2019 -- -- Conference call today at 5:00 p.m. Eastern Time -- MOUNTAIN VIEW, Calif. , May 06, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc.
View HTML
Toggle Summary ChemoCentryx to Hold First Quarter 2019 Financial Results Conference Call on Monday, May 6, 2019
MOUNTAIN VIEW, Calif. , April 29, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's first quarter 2019 financial results will be released after market close on Monday, May 6, 2019 . ChemoCentryx executive management will host a conference call and
View HTML
Toggle Summary ChemoCentryx to Present at the H.C. Wainwright Global Life Sciences Conference
MOUNTAIN VIEW, Calif. , April 02, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference on Monday, April 8, 2019 at 9:10 a.m. BST .
View HTML
Toggle Summary ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors
MOUNTAIN VIEW, Calif. , March 28, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), announced today that, effective March 27, 2019 , Rita Jain , M.D., Senior Vice President and Chief Medical Officer of Akebia Therapeutics , has been appointed to the Company's Board of Directors. Dr.
View HTML
Toggle Summary ChemoCentryx Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights
-- Strong Progress Across Company’s Orphan Disease Franchise of Novel Renal and Dermal Therapeutics -- -- Pivotal top-line data expected from ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA-associated  vasculitis, Q4 -- -- Launched AURORA clinical trial of avacopan in
View HTML
Toggle Summary ChemoCentryx to Hold Fourth Quarter 2018 Financial Results Conference Call on Monday, March 11, 2019
MOUNTAIN VIEW, Calif. , March 04, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's fourth quarter 2018 financial results will be released after market close on Monday, March 11, 2019 . ChemoCentryx executive management will host a conference call
View HTML
Toggle Summary ChemoCentryx to Present at the 8th Annual SVB Leerink Global Healthcare Conference
MOUNTAIN VIEW, Calif. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 10:30 a.m.
View HTML
Toggle Summary ChemoCentryx Announces Withdrawal of Phase II-Based Conditional Marketing Authorization (CMA) Application for ANCA-Associated Vasculitis in Europe; Phase III ADVOCATE Trial Data Release Planned for Q4 2019
-- Companies plan to file for full marketing approval to EMA and FDA in 2020 -- MOUNTAIN VIEW, Calif. and ZURICH, Switzerland, Jan. 24, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma Ltd. , a company of Vifor Pharma Group , today announced that in light of
View HTML
Toggle Summary ChemoCentryx to Present at the 37th Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 1:30 p.m. PST .
View HTML
Toggle Summary ChemoCentryx’s Novel Small Molecule Antagonists of Checkpoint Inhibitors and Chemokine Receptors to be Presented at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Conference
-- Studies highlight CCX4503, a unique small molecule inhibitor of immune checkpoint molecules PD-1/PD-L1, demonstrates anti-tumor efficacy in vivo -- -- Company’s studies also show CCR4 inhibition enhances effectiveness of checkpoint inhibition in tumor models in vivo -- MOUNTAIN VIEW, Calif.
View HTML